Skip navigation | ||
|
||
Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
|
|
|
|
Alternative Names Return to top
CLL; Leukemia - chronic lymphocytic (CLL)Definition Return to top
Chronic lymphocytic leukemia is cancer of the white blood cells (lymphocytes).
Causes Return to top
Chronic lymphocytic leukemia (CLL) causes a slow increase in the number of B lymphocytes in the bone marrow. The cancerous cells spread from the blood marrow to the blood, and can also affect the lymph nodes and other organs. CLL causes the bone marrow to fail and weakens the immune system.
The reason for this increase in B lymphocytes is unknown. There is no link to radiation, cancer-causing chemicals, or viruses.
Usually, the symptoms develop gradually. Many cases are detected by routine blood tests in people with no symptoms.
CLL primarily strikes adults. The average age of a patient with this type of leukemia is 70. It is rarely seen in people younger than 40. The disease is more common in Jewish people of Russian or East European descent, and is uncommon in Asia.
Symptoms Return to top
Exams and Tests Return to top
Patients with CLL have a higher-than-normal white blood cell count.
Tests to diagnose CLL include:
If your doctor discovers you have CLL, tests will be done to see how much the cancer has spread. This is called staging. There are two methods to stage CLL.
There are different ways to stage CLL. One system uses numbers to group CLL into low-, intermediate-, and high-risk categories. Generally, the higher the stage number, the more advanced the cancer. Another system uses letters to stage CLL according to how many lymph node groups are affected and whether or not you have a drop in red blood cells and platelets.
Treatment Return to top
Early stage disease often requires no specific treatment, but it is important to be closely monitored by your doctor.
Chemotherapy may be needed if fatigue, anemia, thrombocytopenia, or lymph node swelling occurs. Several chemotherapy drugs are commonly used to treat CLL. A common drug used is chlorambucil (Leukeran). Fludarabine and cyclophosphamide (Cytoxan) may also be used.
Rituximab (Rituxan), may also be used alone or in combination with traditional chemotherapy. Alemtuzumab (Campath) is approved for treatment of patients with CLL that have not responded to fludarabine.
Rarely, radiation may be used for enlarged lymph nodes. Blood transfusions or platelet transfusions may be required. Stem cell transplantation may be used in advances stages of CLL.
Support Groups Return to top
The stress of illness may be eased by joining a support group whose members share common experiences and problems.
Outlook (Prognosis) Return to top
The outlook depends on the stage of the disease. Half of patients diagnosed in the earliest stages of the disease live more than 12 years. Several new tests that look at cell and genetic changes can help predict life expectancy.
Possible Complications Return to top
When to Contact a Medical Professional Return to top
Call health care provider if you develop enlarged lymph nodes or unexplained fatigue, bruising, excessive sweating, or weight loss.
References Return to top
American Cancer Society. Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society; 2006.
Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKena WG. Clinical Oncology. 3rd ed. Orlando, Fl: Churchill Livingstone; 2004:2921-2940.
Update Date: 9/11/2006 Updated by: Corey Cutler, MD, MPH, FRCP(C), Assistant Professor of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Review provided by VeriMed Healthcare Network.
Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 02 January 2008 |